Stoke Therapeutics (STOK) Non Operating Income (2019 - 2026)
Stoke Therapeutics (STOK) posted quarterly Non Operating Income of $3.4 million for Q1 2026, up 17.07% year-over-year from $2.9 million in Q1 2025, and down 4.18% quarter-over-quarter from $3.6 million in Q4 2025.
Stoke Therapeutics (STOK) Non Operating Income (2019 - 2026) Analysis & Trends
Stoke Therapeutics' Non Operating Income history runs 8 years deep, the most recent figure standing at $3.4 million for Q1 2026.
- In Q1 2026, Non Operating Income rose 17.07% year-over-year to $3.4 million; the TTM figure through Mar 2026 stood at $14.2 million (up 6.94% YoY), while the FY2025 annual figure was $13.7 million, up 10.6% from the prior year.
- Non Operating Income for Q1 2026 stood at $3.4 million, down from $3.6 million in the prior quarter.
- The five-year high for Non Operating Income was $3.8 million in Q2 2025, with the low at $104000.0 in Q1 2022.
- The 5-year median for Non Operating Income is $2.7 million (2023), against an average of $2.5 million.
- The sharpest annual moves came in 2022 and 2024: Non Operating Income soared 4082.35% in 2022, then dropped 6.85% in 2024.
- Stoke Therapeutics' Non Operating Income stood at $1.4 million in 2022, then surged by 94.09% to $2.6 million in 2023, then climbed by 20.66% to $3.2 million in 2024, then increased by 12.39% to $3.6 million in 2025, then retreated by 4.18% to $3.4 million in 2026.
- Business Quant data shows STOK's Non Operating Income at $3.4 million in Q1 2026, $3.6 million in Q4 2025, and $3.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Stoke Therapeutics | 1.95 Bn | 1.66 Bn | - | 3.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.81 Mn |
| Mar 31, 2026 | 3.42 Mn |
| Dec 31, 2025 | 3.56 Mn |
| Sep 30, 2025 | 3.46 Mn |
| Jun 30, 2025 | 3.79 Mn |
| Mar 31, 2025 | 2.92 Mn |
| Dec 31, 2024 | 3.17 Mn |
| Sep 30, 2024 | 3.57 Mn |
| Jun 30, 2024 | 3.65 Mn |
| Mar 31, 2024 | 2.00 Mn |
| Dec 31, 2023 | 2.63 Mn |
| Sep 30, 2023 | 2.65 Mn |
| Jun 30, 2023 | 2.61 Mn |
| Mar 31, 2023 | 2.15 Mn |
| Dec 31, 2022 | 1.35 Mn |
| Sep 30, 2022 | 1.04 Mn |
| Jun 30, 2022 | 544,000.00 |
| Mar 31, 2022 | 104,000.00 |
| Dec 31, 2021 | -34,000.00 |
| Sep 30, 2021 | 86,000.00 |